APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Financial Statements and Exhibits

(d) Exhibits

Aptevo Therapeutics Inc. Exhibit
EX-99.1 2 apvo-ex991_6.htm EX-99.1 apvo-ex991_6.htm   EXHIBIT 99.1   For Immediate Release       APTEVO THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE   $1.5 million of RUXIENCE® Royalties Earned in the Third Quarter   Funding Extends Cash Runway Into 2022   SEATTLE,…
To view the full exhibit click here

About APTEVO THERAPEUTICS INC. (NASDAQ:APVO)

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).